SCHIZOPHRENIA AND SUBSTANCE-RELATED DISORDERS

Schizophrenia and Substance-Related Disorders

Abstract

This study compared health remedy costs of adults with schizophrenia to mature persons with both matter use disorders and schizophrenia. This schizophrenia and substance-related disorders study utilised a paid claims facts and figures base to recognise 6884 mature persons treated for schizophrenia. Twenty per hundred of these furthermore had substance use disorder. We report the charges and prospect of hospitalization for eight widespread health diseases, and the classes of injuries and poisoning, and sick characterised conditions. Multivariate investigates were used to adapt rates of remedy for age and sex dissimilarities in the evaluation groups. There were higher rates of treatment for five of the eight health disorders, higher remedy costs for two of the health disorders and much higher costs for psychiatric treatment among those with comorbid matter use disorders. Both assemblies had high rates of treatment in the categories of wound and poisoning and sick defined conditions. Closer employed relationships among mental wellbeing and wellbeing professionals are needed to care for those with schizophrenia and matter use disorders: first, greater vigilance to the treatment of matter use disorders may advance the wellbeing rank of those with schizophrenia, decrease their exorbitant medical and psychiatric care and stabilize their psychiatric condition, and second, continuity of care amidst professionals may encourage enthusiasm to request health vigilance or alleviate misunderstandings when adults with schizophrenia present with health problems.

Table of Contents

INTRODUCTION5

BACKGROUND6

LITERATURE REVIEW7

METHOD9

Participants9

Material11

Design11

Data Collection11

Data analysis12

REFERENCES15

Schizophrenia and Substance-Related Disorders

Introduction

Adults with schizophrenia who have a comorbid substance use disorder (SUD) represent a major public health problem. Co-existing substance use disorder is likely to increase (1) the difficulty of providing effective psychiatric treatment and (2) medical problems that might otherwise not arise or might respond better to treatment. In addition, several studies using paid insurance claims have reported significantly higher psychiatric expenditures for patients with schizophrenia and comorbid substance use disorder (Garnick, 2007, 2).

The literature on schizophrenia, medical and substance use disorder is a patchwork of information that provides intriguing clues, but no clear picture about their association with each other. The findings from studies of schizophrenia patients with medical disorders are difficult to interpret because most studies have used potentially biased sampling frames or have failed to examine the association between substance use disorders and the prevalence rates of medical disorders. To strengthen the methodology used in examining epidemiological questions about medical co-morbidity, we used 1993 and 1994 data from the Massachusetts Division of Medical Assistance (Medicaid) to compare the one-year treated prevalence of selected medical disorders for adults treated for schizophrenia with a comorbid substance use disorder to those without comorbid substance use disorder.

Background

The reported rates of substance use disorder among those with schizophrenia vary depending on the epidemiological framework used. The prevalence of substance use disorder among these individuals has been reported to be as high as 50%.Mueser et al., using a sample of recently hospitalized patients with schizophrenia, reported lifetime diagnoses of abuse or dependence on the following substances: stimulants 30%, sedatives/hypnotics 6%, ...